Melanotan I
Melanocortin PeptideapprovedAlso known as: Afamelanotide, Scenesse, NDP-α-MSH, CUV1647
A synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that stimulates melanin production for photoprotection, FDA-approved (as Scenesse) for erythropoietic protoporphyria (EPP).
Overview
Melanotan I (afamelanotide) is a synthetic 13-amino acid linear peptide analog of α-MSH developed at the University of Arizona. It is a potent, non-selective melanocortin receptor agonist with highest affinity for MC1R, the primary receptor controlling melanogenesis. Unlike its cyclic relative Melanotan II, MT-I is a linear peptide that acts more selectively on tanning pathways with fewer sexual and appetite-related side effects. It was approved by the FDA in 2019 under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder. Melanotan I increases eumelanin (protective dark pigment) production in the skin, providing photoprotection independent of UV exposure. It has been researched for skin cancer prevention, vitiligo, and polymorphous light eruption.
Mechanism of Action
Melanotan I acts through melanocortin receptor signaling: (1) Binds to MC1R on melanocytes, activating adenylyl cyclase and increasing cAMP levels; (2) Activates the MITF transcription factor, upregulating tyrosinase and melanin synthesis enzymes; (3) Promotes production of eumelanin (brown/black protective pigment) over pheomelanin (red/yellow pigment); (4) Provides photoprotection by increasing the skin's natural UV absorption capacity; (5) Has anti-inflammatory effects mediated through MC1R on immune cells; (6) May have antioxidant properties through melanin-mediated free radical scavenging.
Molecular Formula
C78H111N21O19
Molecular Weight
1646.85 g/mol
Sequence
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Dosage Protocols
Dose Range
16mg – 16mg
Frequency
Every 60 days
Route
subcutaneous implant
Cycle Length
As needed seasonally (typically before/during UV exposure periods)
Scenesse implant is placed subcutaneously above the iliac crest by a healthcare provider. Each implant delivers 16mg over ~60 days.
Source: FDA-approved prescribing information
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
10mg vial
Last Updated
2026-02
Afamelanotide. FDA-approved as Scenesse for EPP. Research vials: $25-50. Brand Scenesse implant: ~$20,000+/yr (specialty).
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Nausea | mild |
| Facial flushing | mild |
| Darkening of existing moles | moderate |
| Headache | mild |
| Injection site reaction | mild |
Pros & Cons
FDA and EMA-approved pharmaceutical with established safety profile from clinical trials
Provides genuine photoprotection by increasing eumelanin production independent of UV exposure
More selective for MC1R than Melanotan II, resulting in fewer sexual and appetite side effects
Potential skin cancer prevention through enhanced natural UV defense
Approved implant (Scenesse) is extremely expensive and only available for EPP diagnosis
Darkening of moles raises concerns about masking melanoma detection
Less potent tanning effect per dose compared to Melanotan II
Long-term safety of off-label cosmetic use not well established
Research Studies
🩸 Blood Work
Liver Function Panel (AST/ALT)
Baseline liver health
Skin Cancer Screening
Stimulates melanogenesis — evaluate existing nevi
Blood Pressure (baseline reading)
Melanocortin peptide may affect BP
More selective than Melanotan II — primarily affects MC1R for pigmentation with fewer systemic effects. Dermatological screening still recommended.
Legal Status
FDA-approved as Scenesse (afamelanotide) implant for EPP. EMA-approved since 2014. Prescription-only for approved indication. Also available as a research chemical for non-approved uses. Banned by WADA.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.
Ipamorelin
A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.